
PubMed:32846167
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 17-23 | Body_part | denotes | xylose | http://purl.org/sig/ont/fma/fma82804 |
T2 | 114-120 | Body_part | denotes | xylose | http://purl.org/sig/ont/fma/fma82804 |
T3 | 496-501 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T4 | 688-693 | Body_part | denotes | lungs | http://purl.org/sig/ont/fma/fma68877 |
T5 | 763-781 | Body_part | denotes | glycosaminoglycans | http://purl.org/sig/ont/fma/fma63011 |
T6 | 783-787 | Body_part | denotes | GAGs | http://purl.org/sig/ont/fma/fma63011 |
T7 | 801-816 | Body_part | denotes | heparan sulfate | http://purl.org/sig/ont/fma/fma63023 |
T8 | 818-820 | Body_part | denotes | HS | http://purl.org/sig/ont/fma/fma63023 |
T9 | 903-905 | Body_part | denotes | HS | http://purl.org/sig/ont/fma/fma63023 |
T10 | 909-913 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T11 | 948-954 | Body_part | denotes | xylose | http://purl.org/sig/ont/fma/fma82804 |
T12 | 1010-1013 | Body_part | denotes | GAG | http://purl.org/sig/ont/fma/fma63011 |
T13 | 1033-1035 | Body_part | denotes | HS | http://purl.org/sig/ont/fma/fma63023 |
T14 | 1076-1080 | Body_part | denotes | GAGs | http://purl.org/sig/ont/fma/fma63011 |
T15 | 1084-1090 | Body_part | denotes | xylose | http://purl.org/sig/ont/fma/fma82804 |
T16 | 1197-1201 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
T17 | 1319-1325 | Body_part | denotes | xylose | http://purl.org/sig/ont/fma/fma82804 |
T18 | 1401-1407 | Body_part | denotes | xylose | http://purl.org/sig/ont/fma/fma82804 |
T19 | 1823-1829 | Body_part | denotes | xylose | http://purl.org/sig/ont/fma/fma82804 |
T20 | 1859-1874 | Body_part | denotes | glucuronic acid | http://purl.org/sig/ont/fma/fma82798 |
T21 | 1876-1895 | Body_part | denotes | N-acetylglucosamine | http://purl.org/sig/ont/fma/fma82787 |
T22 | 1899-1918 | Body_part | denotes | N-acetylglucosamine | http://purl.org/sig/ont/fma/fma82787 |
T23 | 1920-1941 | Body_part | denotes | N-acetylgalactosamine | http://purl.org/sig/ont/fma/fma82786 |
T24 | 1943-1952 | Body_part | denotes | galactose | http://purl.org/sig/ont/fma/fma82794 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 909-913 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
T2 | 1197-1201 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 71-79 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T2 | 141-149 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 155-159 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T4 | 393-408 | Disease | denotes | Type 2 diabetes | http://purl.obolibrary.org/obo/MONDO_0005148 |
T5 | 400-408 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
T6 | 427-447 | Disease | denotes | respiratory diseases | http://purl.obolibrary.org/obo/MONDO_0005087 |
T7 | 449-456 | Disease | denotes | obesity | http://purl.obolibrary.org/obo/MONDO_0011122 |
T8 | 462-474 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T9 | 476-488 | Disease | denotes | Inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T10 | 578-597 | Disease | denotes | respiratory disease | http://purl.obolibrary.org/obo/MONDO_0005087 |
T11 | 626-634 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T12 | 668-680 | Disease | denotes | inflammation | http://purl.obolibrary.org/obo/MONDO_0021166 |
T13 | 709-724 | Disease | denotes | Type 2 diabetes | http://purl.obolibrary.org/obo/MONDO_0005148 |
T14 | 716-724 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
T15 | 914-924 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T16 | 929-944 | Disease | denotes | Type 2 diabetes | http://purl.obolibrary.org/obo/MONDO_0005148 |
T17 | 936-944 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
T18 | 1202-1212 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T19 | 1293-1301 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T20 | 1494-1502 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T21 | 1578-1586 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T22 | 1614-1620 | Disease | denotes | scurvy | http://purl.obolibrary.org/obo/MONDO_0009412 |
T23 | 1675-1682 | Disease | denotes | obesity | http://purl.obolibrary.org/obo/MONDO_0011122 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 215-218 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T2 | 496-501 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T3 | 688-693 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lungs |
T4 | 909-913 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T5 | 909-913 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T6 | 1038-1041 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T7 | 1197-1201 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
T8 | 1197-1201 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
T9 | 1354-1355 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T10 | 1588-1589 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T23 | 1002-1009 | Chemical | denotes | sulfate | http://purl.obolibrary.org/obo/CHEBI_16189 |
T1 | 15-23 | Chemical | denotes | D-xylose | http://purl.obolibrary.org/obo/CHEBI_15936|http://purl.obolibrary.org/obo/CHEBI_53455|http://purl.obolibrary.org/obo/CHEBI_65327 |
T4 | 17-23 | Chemical | denotes | xylose | http://purl.obolibrary.org/obo/CHEBI_18222 |
T5 | 112-120 | Chemical | denotes | D-xylose | http://purl.obolibrary.org/obo/CHEBI_15936|http://purl.obolibrary.org/obo/CHEBI_53455|http://purl.obolibrary.org/obo/CHEBI_65327 |
T8 | 114-120 | Chemical | denotes | xylose | http://purl.obolibrary.org/obo/CHEBI_18222 |
T9 | 125-136 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T10 | 763-781 | Chemical | denotes | glycosaminoglycans | http://purl.obolibrary.org/obo/CHEBI_18085 |
T11 | 783-787 | Chemical | denotes | GAGs | http://purl.obolibrary.org/obo/CHEBI_18085 |
T12 | 801-816 | Chemical | denotes | heparan sulfate | http://purl.obolibrary.org/obo/CHEBI_28815 |
T13 | 801-808 | Chemical | denotes | heparan | http://purl.obolibrary.org/obo/CHEBI_24500 |
T14 | 809-816 | Chemical | denotes | sulfate | http://purl.obolibrary.org/obo/CHEBI_16189 |
T15 | 818-820 | Chemical | denotes | HS | http://purl.obolibrary.org/obo/CHEBI_74056|http://purl.obolibrary.org/obo/CHEBI_28815 |
T17 | 903-905 | Chemical | denotes | HS | http://purl.obolibrary.org/obo/CHEBI_74056|http://purl.obolibrary.org/obo/CHEBI_28815 |
T19 | 946-954 | Chemical | denotes | D-xylose | http://purl.obolibrary.org/obo/CHEBI_15936|http://purl.obolibrary.org/obo/CHEBI_53455|http://purl.obolibrary.org/obo/CHEBI_65327 |
T22 | 948-954 | Chemical | denotes | xylose | http://purl.obolibrary.org/obo/CHEBI_18222 |
T24 | 1010-1013 | Chemical | denotes | GAG | http://purl.obolibrary.org/obo/CHEBI_143889 |
T25 | 1033-1035 | Chemical | denotes | HS | http://purl.obolibrary.org/obo/CHEBI_74056|http://purl.obolibrary.org/obo/CHEBI_28815 |
T27 | 1076-1080 | Chemical | denotes | GAGs | http://purl.obolibrary.org/obo/CHEBI_18085 |
T28 | 1082-1090 | Chemical | denotes | D-xylose | http://purl.obolibrary.org/obo/CHEBI_15936|http://purl.obolibrary.org/obo/CHEBI_53455|http://purl.obolibrary.org/obo/CHEBI_65327 |
T31 | 1084-1090 | Chemical | denotes | xylose | http://purl.obolibrary.org/obo/CHEBI_18222 |
T32 | 1095-1102 | Chemical | denotes | xylitol | http://purl.obolibrary.org/obo/CHEBI_17151 |
T33 | 1154-1163 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T34 | 1243-1254 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T35 | 1317-1325 | Chemical | denotes | D-xylose | http://purl.obolibrary.org/obo/CHEBI_15936|http://purl.obolibrary.org/obo/CHEBI_53455|http://purl.obolibrary.org/obo/CHEBI_65327 |
T38 | 1319-1325 | Chemical | denotes | xylose | http://purl.obolibrary.org/obo/CHEBI_18222 |
T39 | 1326-1333 | Chemical | denotes | xylitol | http://purl.obolibrary.org/obo/CHEBI_17151 |
T40 | 1399-1407 | Chemical | denotes | D-xylose | http://purl.obolibrary.org/obo/CHEBI_15936|http://purl.obolibrary.org/obo/CHEBI_53455|http://purl.obolibrary.org/obo/CHEBI_65327 |
T43 | 1401-1407 | Chemical | denotes | xylose | http://purl.obolibrary.org/obo/CHEBI_18222 |
T44 | 1412-1423 | Chemical | denotes | antibiotics | http://purl.obolibrary.org/obo/CHEBI_33281 |
T45 | 1525-1548 | Chemical | denotes | anti-inflammatory drugs | http://purl.obolibrary.org/obo/CHEBI_35472 |
T46 | 1543-1548 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T47 | 1821-1829 | Chemical | denotes | D-xylose | http://purl.obolibrary.org/obo/CHEBI_15936|http://purl.obolibrary.org/obo/CHEBI_53455|http://purl.obolibrary.org/obo/CHEBI_65327 |
T50 | 1823-1829 | Chemical | denotes | xylose | http://purl.obolibrary.org/obo/CHEBI_18222 |
T51 | 1831-1838 | Chemical | denotes | xylitol | http://purl.obolibrary.org/obo/CHEBI_17151 |
T52 | 1851-1855 | Chemical | denotes | Acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T53 | 1857-1874 | Chemical | denotes | D-glucuronic acid | http://purl.obolibrary.org/obo/CHEBI_4178|http://purl.obolibrary.org/obo/CHEBI_47952|http://purl.obolibrary.org/obo/CHEBI_47953 |
T56 | 1859-1874 | Chemical | denotes | glucuronic acid | http://purl.obolibrary.org/obo/CHEBI_24298 |
T57 | 1870-1874 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T58 | 1876-1895 | Chemical | denotes | N-acetylglucosamine | http://purl.obolibrary.org/obo/CHEBI_28009|http://purl.obolibrary.org/obo/CHEBI_59640 |
T60 | 1899-1918 | Chemical | denotes | N-acetylglucosamine | http://purl.obolibrary.org/obo/CHEBI_28009|http://purl.obolibrary.org/obo/CHEBI_59640 |
T62 | 1920-1941 | Chemical | denotes | N-acetylgalactosamine | http://purl.obolibrary.org/obo/CHEBI_28800 |
T63 | 1943-1952 | Chemical | denotes | galactose | http://purl.obolibrary.org/obo/CHEBI_28260 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T1 | 393-408 | Phenotype | denotes | Type 2 diabetes | http://purl.obolibrary.org/obo/HP_0005978 |
T2 | 449-456 | Phenotype | denotes | obesity | http://purl.obolibrary.org/obo/HP_0001513 |
T3 | 462-474 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
T4 | 532-552 | Phenotype | denotes | respiratory distress | http://purl.obolibrary.org/obo/HP_0002098 |
T5 | 709-724 | Phenotype | denotes | Type 2 diabetes | http://purl.obolibrary.org/obo/HP_0005978 |
T6 | 929-944 | Phenotype | denotes | Type 2 diabetes | http://purl.obolibrary.org/obo/HP_0005978 |
T7 | 1675-1682 | Phenotype | denotes | obesity | http://purl.obolibrary.org/obo/HP_0001513 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 476-488 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | Inflammation |
T2 | 668-680 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammation |
T3 | 748-759 | http://purl.obolibrary.org/obo/GO_0009056 | denotes | degradation |
T4 | 888-899 | http://purl.obolibrary.org/obo/GO_0009056 | denotes | degradation |
T5 | 1048-1060 | http://purl.obolibrary.org/obo/GO_0031099 | denotes | regeneration |
Inflammaging
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-150 | Sentence | denotes | Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19. |
T2 | 151-475 | Sentence | denotes | The SARS-Cov-2 pandemic that currently affects the entire world has been shown to be especially dangerous in the elderly (≥65 years) and in smokers, with notably strong comorbidity in patients already suffering from chronic diseases, such as Type 2 diabetes, cancers, chronic respiratory diseases, obesity, and hypertension. |
T3 | 476-635 | Sentence | denotes | Inflammation of the lungs is the main factor leading to respiratory distress in patients with chronic respiratory disease and in patients with severe COVID-19. |
T4 | 636-822 | Sentence | denotes | Several studies have shown that inflammation of the lungs in general and Type 2 diabetes are accompanied by the degradation of glycosaminoglycans (GAGs), especially heparan sulfate (HS). |
T5 | 823-945 | Sentence | denotes | Several studies have also shown the importance of countering the degradation of HS in lung infections and Type 2 diabetes. |
T6 | 946-1081 | Sentence | denotes | D-xylose, which is the initiating element for different sulfate GAG chains (especially HS), has shown regeneration properties for GAGs. |
T7 | 1082-1255 | Sentence | denotes | D-xylose and xylitol have demonstrated anti-inflammatory, antiglycemic, antiviral, and antibacterial properties in lung infections, alone or in combination with antibiotics. |
T8 | 1256-1587 | Sentence | denotes | Considering the existing research on COVID-19 and related to D-xylose/xylitol, this review offers a perspective on why the association between D-xylose and antibiotics may contribute to significantly reducing the duration of treatment of COVID-19 patients and why some anti-inflammatory drugs may increase the severity of COVID-19. |
T9 | 1588-1708 | Sentence | denotes | A strong correlation with scurvy, based on gender, age, ethnicity, smoking status, and obesity status, is also reviewed. |
T10 | 1709-1800 | Sentence | denotes | Related to this, the effects of treatment with plants such as Artemisia are also addressed. |
T11 | 1801-1953 | Sentence | denotes | CHEMICAL COMPOUNDS: D-xylose; xylitol; l-ascorbic Acid; D-glucuronic acid; N-acetylglucosamine; D-N-acetylglucosamine; N-acetylgalactosamine; galactose. |
T1 | 0-150 | Sentence | denotes | Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19. |
T2 | 151-475 | Sentence | denotes | The SARS-Cov-2 pandemic that currently affects the entire world has been shown to be especially dangerous in the elderly (≥65 years) and in smokers, with notably strong comorbidity in patients already suffering from chronic diseases, such as Type 2 diabetes, cancers, chronic respiratory diseases, obesity, and hypertension. |
T3 | 476-635 | Sentence | denotes | Inflammation of the lungs is the main factor leading to respiratory distress in patients with chronic respiratory disease and in patients with severe COVID-19. |
T4 | 636-822 | Sentence | denotes | Several studies have shown that inflammation of the lungs in general and Type 2 diabetes are accompanied by the degradation of glycosaminoglycans (GAGs), especially heparan sulfate (HS). |
T5 | 823-945 | Sentence | denotes | Several studies have also shown the importance of countering the degradation of HS in lung infections and Type 2 diabetes. |
T6 | 946-1081 | Sentence | denotes | D-xylose, which is the initiating element for different sulfate GAG chains (especially HS), has shown regeneration properties for GAGs. |
T7 | 1082-1255 | Sentence | denotes | D-xylose and xylitol have demonstrated anti-inflammatory, antiglycemic, antiviral, and antibacterial properties in lung infections, alone or in combination with antibiotics. |
T8 | 1256-1587 | Sentence | denotes | Considering the existing research on COVID-19 and related to D-xylose/xylitol, this review offers a perspective on why the association between D-xylose and antibiotics may contribute to significantly reducing the duration of treatment of COVID-19 patients and why some anti-inflammatory drugs may increase the severity of COVID-19. |
T9 | 1588-1708 | Sentence | denotes | A strong correlation with scurvy, based on gender, age, ethnicity, smoking status, and obesity status, is also reviewed. |
T10 | 1709-1800 | Sentence | denotes | Related to this, the effects of treatment with plants such as Artemisia are also addressed. |
T11 | 1801-1953 | Sentence | denotes | CHEMICAL COMPOUNDS: D-xylose; xylitol; l-ascorbic Acid; D-glucuronic acid; N-acetylglucosamine; D-N-acetylglucosamine; N-acetylgalactosamine; galactose. |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-150 | Sentence | denotes | Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19. |
T2 | 151-475 | Sentence | denotes | The SARS-Cov-2 pandemic that currently affects the entire world has been shown to be especially dangerous in the elderly (≥65 years) and in smokers, with notably strong comorbidity in patients already suffering from chronic diseases, such as Type 2 diabetes, cancers, chronic respiratory diseases, obesity, and hypertension. |
T3 | 476-635 | Sentence | denotes | Inflammation of the lungs is the main factor leading to respiratory distress in patients with chronic respiratory disease and in patients with severe COVID-19. |
T4 | 636-822 | Sentence | denotes | Several studies have shown that inflammation of the lungs in general and Type 2 diabetes are accompanied by the degradation of glycosaminoglycans (GAGs), especially heparan sulfate (HS). |
T5 | 823-945 | Sentence | denotes | Several studies have also shown the importance of countering the degradation of HS in lung infections and Type 2 diabetes. |
T6 | 946-1081 | Sentence | denotes | D-xylose, which is the initiating element for different sulfate GAG chains (especially HS), has shown regeneration properties for GAGs. |
T7 | 1082-1255 | Sentence | denotes | D-xylose and xylitol have demonstrated anti-inflammatory, antiglycemic, antiviral, and antibacterial properties in lung infections, alone or in combination with antibiotics. |
T8 | 1256-1587 | Sentence | denotes | Considering the existing research on COVID-19 and related to D-xylose/xylitol, this review offers a perspective on why the association between D-xylose and antibiotics may contribute to significantly reducing the duration of treatment of COVID-19 patients and why some anti-inflammatory drugs may increase the severity of COVID-19. |
T9 | 1588-1708 | Sentence | denotes | A strong correlation with scurvy, based on gender, age, ethnicity, smoking status, and obesity status, is also reviewed. |
T10 | 1709-1800 | Sentence | denotes | Related to this, the effects of treatment with plants such as Artemisia are also addressed. |
T11 | 1801-1953 | Sentence | denotes | CHEMICAL COMPOUNDS: D-xylose; xylitol; l-ascorbic Acid; D-glucuronic acid; N-acetylglucosamine; D-N-acetylglucosamine; N-acetylgalactosamine; galactose. |
LitCovid-PD-GlycoEpitope
Id | Subject | Object | Predicate | Lexical cue | glyco_epitope_db_id |
---|---|---|---|---|---|
T1 | 801-816 | GlycoEpitope | denotes | heparan sulfate | http://www.glycoepitope.jp/epitopes/EP0086 |
T2 | 818-820 | GlycoEpitope | denotes | HS | http://www.glycoepitope.jp/epitopes/EP0086 |
T3 | 903-905 | GlycoEpitope | denotes | HS | http://www.glycoepitope.jp/epitopes/EP0086 |
T4 | 1033-1035 | GlycoEpitope | denotes | HS | http://www.glycoepitope.jp/epitopes/EP0086 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
4 | 15-23 | Chemical | denotes | D-xylose | MESH:D014994 |
5 | 71-79 | Disease | denotes | COVID-19 | MESH:C000657245 |
6 | 112-120 | Chemical | denotes | D-xylose | MESH:D014994 |
7 | 141-149 | Disease | denotes | COVID-19 | MESH:C000657245 |
53 | 155-165 | Species | denotes | SARS-Cov-2 | Tax:2697049 |
54 | 335-343 | Species | denotes | patients | Tax:9606 |
55 | 367-383 | Disease | denotes | chronic diseases | MESH:D002908 |
56 | 393-408 | Disease | denotes | Type 2 diabetes | MESH:D003924 |
57 | 410-417 | Disease | denotes | cancers | MESH:D009369 |
58 | 427-447 | Disease | denotes | respiratory diseases | MESH:D012140 |
59 | 449-456 | Disease | denotes | obesity | MESH:D009765 |
60 | 462-474 | Disease | denotes | hypertension | MESH:D006973 |
61 | 476-488 | Disease | denotes | Inflammation | MESH:D007249 |
62 | 532-552 | Disease | denotes | respiratory distress | MESH:D012128 |
63 | 556-564 | Species | denotes | patients | Tax:9606 |
64 | 578-597 | Disease | denotes | respiratory disease | MESH:D012140 |
65 | 605-613 | Species | denotes | patients | Tax:9606 |
66 | 626-634 | Disease | denotes | COVID-19 | MESH:C000657245 |
67 | 668-680 | Disease | denotes | inflammation | MESH:D007249 |
68 | 716-724 | Disease | denotes | diabetes | MESH:D003920 |
69 | 763-781 | Chemical | denotes | glycosaminoglycans | MESH:D006025 |
70 | 783-787 | Chemical | denotes | GAGs | MESH:D006025 |
71 | 801-816 | Chemical | denotes | heparan sulfate | MESH:D006497 |
72 | 818-820 | Chemical | denotes | HS | MESH:D006497 |
73 | 909-924 | Disease | denotes | lung infections | MESH:D012141 |
74 | 929-944 | Disease | denotes | Type 2 diabetes | MESH:D003924 |
75 | 946-954 | Chemical | denotes | D-xylose | MESH:D014994 |
76 | 1010-1013 | Chemical | denotes | GAG | MESH:D006025 |
77 | 1033-1035 | Chemical | denotes | HS | MESH:D006497 |
78 | 1076-1080 | Chemical | denotes | GAGs | MESH:D006025 |
79 | 1082-1090 | Chemical | denotes | D-xylose | MESH:D014994 |
80 | 1095-1102 | Chemical | denotes | xylitol | MESH:D014993 |
81 | 1197-1212 | Disease | denotes | lung infections | MESH:D012141 |
82 | 1293-1301 | Disease | denotes | COVID-19 | MESH:C000657245 |
83 | 1317-1325 | Chemical | denotes | D-xylose | MESH:D014994 |
84 | 1326-1333 | Chemical | denotes | xylitol | MESH:D014993 |
85 | 1399-1407 | Chemical | denotes | D-xylose | MESH:D014994 |
86 | 1494-1502 | Disease | denotes | COVID-19 | MESH:C000657245 |
87 | 1503-1511 | Species | denotes | patients | Tax:9606 |
88 | 1578-1586 | Disease | denotes | COVID-19 | MESH:C000657245 |
89 | 1675-1689 | Disease | denotes | obesity status | MESH:D009765 |
90 | 1821-1829 | Chemical | denotes | D-xylose | MESH:D014994 |
91 | 1831-1838 | Chemical | denotes | xylitol | MESH:D014993 |
92 | 1840-1855 | Chemical | denotes | l-ascorbic Acid | MESH:D001205 |
93 | 1857-1874 | Chemical | denotes | D-glucuronic acid | MESH:D020723 |
94 | 1876-1895 | Chemical | denotes | N-acetylglucosamine | MESH:D000117 |
95 | 1897-1918 | Chemical | denotes | D-N-acetylglucosamine | |
96 | 1920-1941 | Chemical | denotes | N-acetylgalactosamine | MESH:D000116 |
97 | 1943-1952 | Chemical | denotes | galactose | MESH:D005690 |